Announcement on Receiving the Approval Notice for the Chemical API Market Application of a Wholly-Owned Subsidiary

Jiangxi Fushine Pharmaceutical Co., Ltd.·July 2, 2026·2 pages

✨ AI Summary

Jiangxi Fuxiang Pharmaceutical Co., Ltd. announces its wholly-owned subsidiary, Jiangxi Xiangtai Life Science Co., Ltd., has received approval from the NMPA for its Torasemide API market application. This approval allows for domestic sales, enriching the company's product line and potentially boosting pharmaceutical raw material sales. The company anticipates a positive impact on performance, though market sales depend on various external factors.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300497

Securities Abbreviation: Fuxiang Shares

Announcement No.: 2026-064

Jiangxi Fuxiang Pharmaceutical Co., Ltd.

Announcement on Receiving the Approval Notice for the Chemical API Market Application of a Wholly-Owned Subsidiary

The Company and all members of the Board of Directors guarantee the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.

Recently, Jiangxi Fuxiang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company")'s wholly-owned subsidiary, Jiangxi Xiangtai Life Science Co., Ltd. (hereinafter referred to as "Xiangtai Science"), received the Approval Notice for the Chemical API Market Application issued by the National Medical Products Administration for Torasemide API. The relevant situation is now announced as follows:

I. Basic Information of the Drug

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.